Affiliation:
1. Department of Cardiology The Second Affiliated Hospital of Army Medical University Chongqing China
2. Laboratory of Cardiovascular Mosaicism National Cerebral and Cardiovascular Center Osaka Japan
Abstract
AbstractHematopoietic mosaic loss of Y chromosome (mLOY) has emerged as a potential male‐specific accelerator of biological aging, increasing the risk of various age‐related diseases, including cancer. Importantly, mLOY is not confined to hematopoietic cells; its presence has also been observed in nonhematological cancer cells, with the impact of this presence previously unknown. Recent studies have revealed that, whether occurring in leukocytes or cancer cells, mLOY plays a role in promoting the development of an immunosuppressive tumor microenvironment. This occurs through the modulation of tumor‐infiltrating immune cells, ultimately enabling cancer cells to evade the vigilant immune system. In this review, we illuminate recent progress concerning the effects of hematopoietic mLOY and cancer mLOY on cancer progression. Examining cancer progression from the perspective of LOY adds a new layer to our understanding of cancer immunity, promising insights that hold the potential to identify innovative and potent immunotherapy targets for cancer.
Funder
Novartis
Kondou Kinen Medical Foundation
Mochida Memorial Foundation for Medical and Pharmaceutical Research
MSD Life Science Foundation, Public Interest Incorporated Foundation
Japan Cardiovascular Research Foundation
SENSHIN Medical Research Foundation
National Natural Science Foundation of China
Japanese Circulation Society
Bayer
Subject
Cancer Research,Oncology,General Medicine